| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 30 | 2024 | 2668 | 3.100 |
Why?
|
| Osteoblasts | 8 | 2024 | 394 | 1.790 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2024 | 2417 | 1.390 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2024 | 303 | 1.370 |
Why?
|
| Fracture Fixation, Intramedullary | 5 | 2022 | 41 | 1.290 |
Why?
|
| Osteolysis | 5 | 2024 | 99 | 1.220 |
Why?
|
| Kidney Neoplasms | 6 | 2024 | 3153 | 1.100 |
Why?
|
| Tibia | 4 | 2020 | 127 | 0.970 |
Why?
|
| Osteocytes | 1 | 2024 | 35 | 0.940 |
Why?
|
| Gap Junctions | 1 | 2024 | 50 | 0.930 |
Why?
|
| Cadherins | 5 | 2023 | 676 | 0.930 |
Why?
|
| Adamantinoma | 1 | 2020 | 7 | 0.750 |
Why?
|
| Cell Communication | 4 | 2017 | 518 | 0.720 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2023 | 917 | 0.640 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2020 | 135 | 0.630 |
Why?
|
| Anilides | 2 | 2020 | 296 | 0.610 |
Why?
|
| Capitate Bone | 1 | 2017 | 5 | 0.590 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2017 | 53 | 0.570 |
Why?
|
| Transforming Growth Factor beta | 2 | 2024 | 1133 | 0.560 |
Why?
|
| Sarcoma | 7 | 2024 | 1842 | 0.560 |
Why?
|
| Prostatic Neoplasms | 11 | 2024 | 5996 | 0.550 |
Why?
|
| Clathrin | 1 | 2015 | 37 | 0.520 |
Why?
|
| Coculture Techniques | 4 | 2020 | 631 | 0.500 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2017 | 235 | 0.500 |
Why?
|
| Fractures, Spontaneous | 4 | 2018 | 87 | 0.490 |
Why?
|
| Orthopedics | 2 | 2010 | 80 | 0.490 |
Why?
|
| Endocytosis | 1 | 2015 | 239 | 0.480 |
Why?
|
| Femoral Neoplasms | 6 | 2018 | 66 | 0.470 |
Why?
|
| Bone and Bones | 5 | 2024 | 612 | 0.450 |
Why?
|
| Pyridines | 2 | 2020 | 1312 | 0.440 |
Why?
|
| Cell Differentiation | 5 | 2023 | 4195 | 0.440 |
Why?
|
| Apoptosis | 3 | 2024 | 7837 | 0.430 |
Why?
|
| Bone Nails | 3 | 2022 | 32 | 0.420 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 108 | 0.420 |
Why?
|
| Stereotaxic Techniques | 1 | 2013 | 184 | 0.420 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 584 | 0.410 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3022 | 0.400 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 244 | 0.380 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 261 | 0.380 |
Why?
|
| Femoral Fractures | 3 | 2018 | 65 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 10365 | 0.350 |
Why?
|
| Mice, SCID | 5 | 2020 | 1851 | 0.350 |
Why?
|
| Bone Marrow Cells | 3 | 2009 | 983 | 0.350 |
Why?
|
| Astronauts | 1 | 2010 | 58 | 0.340 |
Why?
|
| Stromal Cells | 3 | 2009 | 835 | 0.320 |
Why?
|
| Limb Salvage | 3 | 2021 | 166 | 0.320 |
Why?
|
| Cell Movement | 2 | 2015 | 2504 | 0.320 |
Why?
|
| Femur | 4 | 2023 | 162 | 0.310 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 14875 | 0.290 |
Why?
|
| Telemedicine | 1 | 2014 | 549 | 0.290 |
Why?
|
| Calcification, Physiologic | 3 | 2017 | 55 | 0.290 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2013 | 101 | 0.280 |
Why?
|
| Bone Cements | 2 | 2024 | 50 | 0.280 |
Why?
|
| Cementation | 2 | 2024 | 10 | 0.280 |
Why?
|
| Humans | 56 | 2024 | 271884 | 0.280 |
Why?
|
| Osteogenesis | 2 | 2023 | 271 | 0.270 |
Why?
|
| Medical Oncology | 2 | 2017 | 1463 | 0.270 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 3363 | 0.270 |
Why?
|
| Cell Proliferation | 5 | 2020 | 7300 | 0.260 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 5804 | 0.240 |
Why?
|
| Pelvic Neoplasms | 2 | 2024 | 203 | 0.240 |
Why?
|
| Connexin 43 | 1 | 2024 | 46 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 9099 | 0.230 |
Why?
|
| Animals | 18 | 2024 | 62807 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2024 | 102 | 0.220 |
Why?
|
| Diaphyses | 1 | 2023 | 11 | 0.220 |
Why?
|
| Ossification, Heterotopic | 2 | 2015 | 70 | 0.220 |
Why?
|
| Acetabulum | 1 | 2003 | 41 | 0.220 |
Why?
|
| Evoked Potentials, Motor | 1 | 2003 | 60 | 0.210 |
Why?
|
| Sciatic Nerve | 1 | 2003 | 123 | 0.210 |
Why?
|
| Mice | 12 | 2024 | 36041 | 0.200 |
Why?
|
| Male | 35 | 2024 | 128957 | 0.200 |
Why?
|
| Disease Progression | 3 | 2024 | 6909 | 0.200 |
Why?
|
| Humerus | 2 | 2023 | 51 | 0.190 |
Why?
|
| Liposarcoma | 1 | 2024 | 248 | 0.190 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 265 | 0.190 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2024 | 299 | 0.190 |
Why?
|
| Lipoma | 1 | 2021 | 94 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 5186 | 0.180 |
Why?
|
| Osteonecrosis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Surgical Oncology | 1 | 2023 | 208 | 0.180 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 18 | 0.170 |
Why?
|
| Reoperation | 6 | 2023 | 1389 | 0.170 |
Why?
|
| Orthopedic Procedures | 3 | 2019 | 144 | 0.170 |
Why?
|
| Adiposity | 1 | 2021 | 238 | 0.170 |
Why?
|
| Female | 27 | 2024 | 149143 | 0.160 |
Why?
|
| Frozen Sections | 1 | 2019 | 118 | 0.160 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 296 | 0.160 |
Why?
|
| Radiography | 4 | 2017 | 1993 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5330 | 0.160 |
Why?
|
| Allografts | 1 | 2020 | 684 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 3928 | 0.160 |
Why?
|
| Drainage | 1 | 2021 | 448 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 229 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2021 | 284 | 0.160 |
Why?
|
| Plasmacytoma | 1 | 2019 | 123 | 0.150 |
Why?
|
| Bone Diseases | 1 | 2019 | 142 | 0.150 |
Why?
|
| Hip Fractures | 1 | 2018 | 88 | 0.150 |
Why?
|
| Chondrosarcoma | 1 | 2019 | 213 | 0.140 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 1742 | 0.140 |
Why?
|
| Treatment Outcome | 14 | 2024 | 33863 | 0.140 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 138 | 0.140 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2009 | 135 | 0.140 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 272 | 0.140 |
Why?
|
| Rats | 6 | 2010 | 6638 | 0.140 |
Why?
|
| Middle Aged | 20 | 2024 | 90395 | 0.140 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 469 | 0.130 |
Why?
|
| Patella | 1 | 2016 | 39 | 0.130 |
Why?
|
| Postoperative Complications | 4 | 2021 | 5690 | 0.130 |
Why?
|
| Leg Length Inequality | 1 | 2015 | 12 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2017 | 261 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 534 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 731 | 0.130 |
Why?
|
| Heterografts | 1 | 2017 | 745 | 0.130 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 39 | 0.120 |
Why?
|
| Osteosarcoma | 3 | 2015 | 948 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 726 | 0.120 |
Why?
|
| Femur Neck | 1 | 2014 | 21 | 0.120 |
Why?
|
| Cell Shape | 1 | 2015 | 130 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1472 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 217 | 0.120 |
Why?
|
| Exosomes | 1 | 2017 | 253 | 0.120 |
Why?
|
| Retrospective Studies | 15 | 2023 | 39780 | 0.120 |
Why?
|
| Hydrogels | 1 | 2015 | 131 | 0.120 |
Why?
|
| Biopsy | 2 | 2019 | 3544 | 0.120 |
Why?
|
| Hyaluronic Acid | 1 | 2015 | 152 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 344 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2010 | 2255 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 852 | 0.110 |
Why?
|
| Osteotomy | 1 | 2014 | 105 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2021 | 2435 | 0.110 |
Why?
|
| Cell Separation | 1 | 2015 | 616 | 0.110 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 32 | 0.110 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 426 | 0.110 |
Why?
|
| Aged | 16 | 2024 | 73471 | 0.100 |
Why?
|
| Aged, 80 and over | 10 | 2023 | 31042 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 582 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 281 | 0.100 |
Why?
|
| Young Adult | 7 | 2021 | 22108 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 1143 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1470 | 0.100 |
Why?
|
| Adult | 16 | 2024 | 81857 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2011 | 103 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 7822 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1085 | 0.090 |
Why?
|
| Humeral Fractures | 1 | 2011 | 23 | 0.090 |
Why?
|
| Time Factors | 6 | 2015 | 13130 | 0.090 |
Why?
|
| Nanofibers | 1 | 2010 | 22 | 0.090 |
Why?
|
| Bone Regeneration | 1 | 2010 | 35 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 5211 | 0.090 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 70 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1212 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 7929 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2019 | 1368 | 0.090 |
Why?
|
| Gene Expression | 1 | 2017 | 3689 | 0.080 |
Why?
|
| Proteins | 1 | 2017 | 2058 | 0.080 |
Why?
|
| Cell Survival | 1 | 2015 | 3074 | 0.080 |
Why?
|
| Protein Binding | 1 | 2015 | 3528 | 0.080 |
Why?
|
| Neoplasms | 2 | 2014 | 15915 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 366 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2014 | 3646 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3651 | 0.070 |
Why?
|
| Internship and Residency | 1 | 1999 | 1437 | 0.070 |
Why?
|
| Titanium | 1 | 2007 | 62 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 2286 | 0.070 |
Why?
|
| Nanostructures | 1 | 2007 | 102 | 0.070 |
Why?
|
| Adolescent | 7 | 2022 | 32663 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 1599 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6270 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 14653 | 0.060 |
Why?
|
| Hemangioblastoma | 1 | 2005 | 29 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2015 | 6489 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 5421 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7471 | 0.060 |
Why?
|
| Pregnancy | 1 | 2017 | 8100 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 157 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 370 | 0.060 |
Why?
|
| Phenotype | 1 | 2015 | 6515 | 0.060 |
Why?
|
| Methylmethacrylate | 1 | 2003 | 17 | 0.060 |
Why?
|
| Heart Arrest, Induced | 1 | 2003 | 85 | 0.060 |
Why?
|
| Sciatic Neuropathy | 1 | 2003 | 12 | 0.050 |
Why?
|
| Weight-Bearing | 1 | 2003 | 64 | 0.050 |
Why?
|
| Estrogens | 1 | 2007 | 844 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2003 | 195 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2010 | 1730 | 0.050 |
Why?
|
| Electromyography | 1 | 2003 | 232 | 0.050 |
Why?
|
| Bone Remodeling | 1 | 2023 | 102 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 177 | 0.050 |
Why?
|
| Survival Rate | 3 | 2019 | 12533 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 15267 | 0.050 |
Why?
|
| Peptides | 1 | 2007 | 1528 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4964 | 0.050 |
Why?
|
| Extremities | 1 | 2023 | 309 | 0.050 |
Why?
|
| Risk Factors | 4 | 2023 | 18045 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 4495 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2005 | 486 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2001 | 222 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 2496 | 0.040 |
Why?
|
| Prognosis | 4 | 2019 | 22537 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2006 | 3078 | 0.040 |
Why?
|
| Leptin | 1 | 2021 | 312 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2003 | 691 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 716 | 0.040 |
Why?
|
| Adipocytes | 1 | 2021 | 308 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 1999 | 68 | 0.040 |
Why?
|
| Child | 5 | 2021 | 30492 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13993 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 259 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2003 | 640 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2010 | 245 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 5118 | 0.040 |
Why?
|
| Schools, Medical | 1 | 1999 | 132 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1313 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2014 | 1741 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1053 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 1429 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 36 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 4889 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 5861 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2129 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2019 | 9325 | 0.030 |
Why?
|
| Fracture Healing | 1 | 2016 | 43 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1950 | 0.030 |
Why?
|
| Research | 1 | 1999 | 431 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 9044 | 0.030 |
Why?
|
| Health Policy | 1 | 1999 | 280 | 0.030 |
Why?
|
| Epiphyses | 1 | 2015 | 14 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1999 | 439 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10750 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 112 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6210 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 909 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1402 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 10259 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 2054 | 0.030 |
Why?
|
| Curettage | 1 | 2014 | 22 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 16610 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 1999 | 632 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 2270 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 562 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 2013 | 128 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 4968 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2013 | 110 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 715 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2017 | 5787 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 7975 | 0.030 |
Why?
|
| United States | 1 | 2010 | 16050 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 16241 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1999 | 876 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2011 | 71 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 4071 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2011 | 58 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 5432 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 1100 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2011 | 93 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 257 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 4003 | 0.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 879 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1041 | 0.020 |
Why?
|
| Tibial Fractures | 1 | 2011 | 63 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 5195 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5928 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 663 | 0.020 |
Why?
|
| Tomography | 1 | 2010 | 63 | 0.020 |
Why?
|
| Proteomics | 1 | 2017 | 1437 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1827 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2335 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3978 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 2035 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2007 | 21 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2006 | 12222 | 0.020 |
Why?
|
| Porosity | 1 | 2007 | 56 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 673 | 0.020 |
Why?
|
| Pain | 1 | 2016 | 1696 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 343 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 6883 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 4352 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 9491 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2429 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3853 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2007 | 532 | 0.020 |
Why?
|
| Factor XIIIa | 1 | 2005 | 4 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 3072 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 170 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2005 | 90 | 0.020 |
Why?
|
| Inhibins | 1 | 2005 | 126 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2005 | 190 | 0.020 |
Why?
|
| Vimentin | 1 | 2005 | 260 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 2439 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2010 | 1660 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 643 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13931 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 16999 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Cytokines | 1 | 2011 | 2840 | 0.010 |
Why?
|
| Estradiol | 1 | 2005 | 881 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 2005 | 743 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 2469 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2001 | 275 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 3165 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2011 | 3664 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2005 | 4359 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2242 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 2711 | 0.010 |
Why?
|
| Mutation | 1 | 2013 | 15924 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 12012 | 0.010 |
Why?
|